|
- 2018
Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertensionKeywords: treprostinil, pulmonary arterial hypertension Abstract: Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil
|